Filtered By:
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 1913 results found since Jan 2013.
Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
ConclusionsIn these T2DM patients with ACS, a significantly lower risk of major adverse cardiovascular events including all-cause mortality was observed in the ticagrelor group compared with the clopidogrel group. However, T2DM patients who were assigned to ticagrelor showed a significantly higher minor bleeding risk. Larger clinical trials should be able to confirm these hypotheses.
Source: Diabetes Therapy - December 21, 2022 Category: Endocrinology Source Type: research
Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial
Conclusions: Dual antiplatelet treatment was safe for minor stroke or high-risk TIA patients with mildly elevated aminotransferase. Mild elevation of ALT or AST did not undermine the protective efficacy of the dual antiplatelet regimen in reducing recurrent stroke or TIA within 90 days after MIS or TIA. The interaction between the CYP2C19 loss-of-function allele carrier status and aminotransferase level on the efficacy of dual antiplatelet treatment was not observed.Cerebrovasc Dis
Source: Cerebrovascular Diseases - December 9, 2022 Category: Neurology Source Type: research
In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality
Ann Intern Med. 2022 Dec 6. doi: 10.7326/J22-0094. Online ahead of print.NO ABSTRACTPMID:36469913 | DOI:10.7326/J22-0094
Source: Annals of Internal Medicine - December 5, 2022 Category: Internal Medicine Authors: Akshay Goel Aaqib H Malik Source Type: research
Multi-institutional patterns of clopidogrel response among patients undergoing transcarotid artery revascularization
CONCLUSIONS: Using preoperative P2Y12 testing with a threshold PRU ≥ 194 to define CR, we identified a high prevalence of CR in patients undergoing TCAR similar to that in the pre-existing coronary literature. We found no significant differences in postoperative ischemic or hemorrhagic complications by clopidogrel response phenotype, although complication rates in the overall study cohort were low. CR may be a spectrum from responder to partial responder to complete non-responder, and this may account for the differences in our CR cohort compared to the ROADSTER 2 protocol deviation cohort. Further investigation is warra...
Source: Vascular - November 25, 2022 Category: Surgery Authors: Rae S Rokosh Caron Rockman Karan Garg Shihuan Keisin Wang Raghu L Motaganahalli Andrew C Schroeder Peter J Sobraske Michael C Stoner Yauhen A Tarbunou Rebecca A Marmor Mahmoud B Malas Thomas S Maldonado Source Type: research
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study
The objective of this study was to evaluate cardiovascular events based on ticagrelor, prasugrel, and clopidogrel use in a real-world patient setting. This retrospective cohort study used the IBM MarketScan database (January 1st, 2013, to December 31st, 2018) to create 3 propensity score-matched pairs: ticagrelor vs. clopidogrel (N=21,719), prasugrel vs. clopidogrel (N=11,513), and prasugrel vs. ticagrelor (N=11,065). The primary outcome was a composite of myocardial ischemia, unstable angina, stroke, and heart failure hospitalization. These groups were compared in a time-to-event analysis for the primary outcome at 30, 90...
Source: Clinical Pharmacology and Therapeutics - November 18, 2022 Category: Drugs & Pharmacology Authors: Arun Kumar Pamela L Lutsey Wendy L St Peter Jon C Schommer Jeremy R Van't Hof Abhijeet Rajpurohit Joel F Farley Source Type: research
